Literature DB >> 31309519

Intravenous immunoglobulin therapy: a snapshot for the internist.

Gianfranco Vitiello1, Giacomo Emmi2, Elena Silvestri2, Gerardo Di Scala2, Boaz Palterer2, Paola Parronchi2.   

Abstract

Intravenous immunoglobulins are the cornerstone for the treatment of primary humoral immunodeficiencies and may be used for a great number of other autoimmune, neurological and hematological conditions as well. Given their wide application, the possibility of running across a patient who needs this kind of therapy is becoming increasingly common. Generally, intravenous immunoglobulins are well tolerated. However, numerous adverse reactions ranging from mild to severe have been reported and linked to patient- and product-related factors. For all these reasons, we present herein a comprehensive review of the on- and off-label applications of intravenous immunoglobulins and provide a guide for the internist how to minimize the risk of adverse reactions and manage them.

Entities:  

Keywords:  Adverse drug reactions; Autoimmune diseases; IVIg; Immunodeficiency; Immunoglobulins

Mesh:

Year:  2019        PMID: 31309519     DOI: 10.1007/s11739-019-02150-z

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   5.472


  56 in total

Review 1.  Thrombosis in Autoimmune Diseases: A Role for Immunosuppressive Treatments?

Authors:  Elena Silvestri; Antonella Scalera; Giacomo Emmi; Danilo Squatrito; Lucia Ciucciarelli; Caterina Cenci; Carlo Tamburini; Lorenzo Emmi; Giovanni Di Minno; Domenico Prisco
Journal:  Semin Thromb Hemost       Date:  2016-06-06       Impact factor: 4.180

2.  Hospital-associated venous thromboembolism in children: incidence and clinical characteristics.

Authors:  Clifford M Takemoto; Sajeet Sohi; Kruti Desai; Raman Bharaj; Anuj Khanna; Susan McFarland; Sybil Klaus; Alia Irshad; Neil A Goldenberg; John J Strouse; Michael B Streiff
Journal:  J Pediatr       Date:  2013-12-12       Impact factor: 4.406

Review 3.  Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk.

Authors:  Jacques Dantal
Journal:  Am J Nephrol       Date:  2013-09-14       Impact factor: 3.754

Review 4.  Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin?

Authors:  Fatima Dhalla; Mary Lucas; Anna Schuh; Malini Bhole; Rashmi Jain; Smita Y Patel; Siraj Misbah; Helen Chapel
Journal:  J Clin Immunol       Date:  2014-02-21       Impact factor: 8.317

5.  Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.

Authors:  M D Mignogna; G Fortuna; S Leuci; E Ruoppo; D Adamo; S Fedele
Journal:  Clin Exp Dermatol       Date:  2009-03       Impact factor: 3.470

6.  Variations in serum hemoglobin, albumin, and electrolytes in patients receiving intravenous immunoglobulin therapy: a real clinical threat?

Authors:  Michele D Mignogna; Giulio Fortuna; Elvira Ruoppo; Daniela Adamo; Stefania Leuci; Stefano Fedele
Journal:  Am J Clin Dermatol       Date:  2007       Impact factor: 7.403

Review 7.  History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Authors:  P James B Dyck; Jennifer A Tracy
Journal:  Mayo Clin Proc       Date:  2018-06       Impact factor: 7.616

Review 8.  Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects.

Authors:  Andrea Matucci; Enrico Maggi; Alessandra Vultaggio
Journal:  Front Immunol       Date:  2015-01-12       Impact factor: 7.561

Review 9.  Specific Antibody Deficiency: Controversies in Diagnosis and Management.

Authors:  Elena Perez; Francisco A Bonilla; Jordan S Orange; Mark Ballow
Journal:  Front Immunol       Date:  2017-05-22       Impact factor: 7.561

10.  Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.

Authors:  Clementina Canessa; Jessica Iacopelli; Antonio Pecoraro; Giuseppe Spadaro; Andrea Matucci; Cinzia Milito; Alessandra Vultaggio; Carlo Agostini; Francesco Cinetto; Maria Giovanna Danieli; Simona Gambini; Carolina Marasco; Antonino Trizzino; Angelo Vacca; Domenico De Mattia; Baldassarre Martire; Alessandro Plebani; Mario Di Gioacchino; Alessia Gatta; Andrea Finocchi; Francesco Licciardi; Silvana Martino; Marco De Carli; Viviana Moschese; Chiara Azzari
Journal:  Int J Immunopathol Pharmacol       Date:  2016-12-07       Impact factor: 3.219

View more
  3 in total

1.  Fulminant Guillain-Barré Syndrome and Spontaneous Intraventricular Hemorrhage: A Case Report and Literature Review.

Authors:  Jun Hu; Xiaoqian Luo; Yu Wang; Eric Prado; Qinghui Fu; Anwen Shao
Journal:  Front Neurosci       Date:  2020-06-30       Impact factor: 4.677

2.  Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis.

Authors:  Emilie Jacque; Claire Chottin; Daphné Laubreton; Michel Nogre; Cécile Ferret; Sandrine de Marcos; Linda Baptista; Carole Drajac; Philippe Mondon; Christophe De Romeuf; Marie-Anne Rameix-Welti; Jean-François Eléouët; Sami Chtourou; Sabine Riffault; Gérald Perret; Delphyne Descamps
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561

3.  Fulminant Guillain-Barré Syndrome Post Hemorrhagic Stroke: Two Case Reports.

Authors:  Sameeh Abdulmana; Naif Al-Zahrani; Yahya Sharahely; Shahid Bashir; Talal M Al-Harbi
Journal:  Neurol Int       Date:  2021-05-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.